25 results
8-K
EX-10.1
NVTAQ
Invitae Corp
5 Jul 23
Departure of Directors or Certain Officers
4:53pm
that conflicts with this Agreement or otherwise creates a conflict of interest with Consultant’s Services.
10.Term; Termination. This Agreement is effective
PRE 14A
NVTAQ
Invitae Corp
4 Apr 22
Preliminary proxy
4:15pm
for potential conflict of interest situations on an ongoing basis and all such transactions relating to executive officers and directors must be approved by our
8-K
EX-10.1
x9i4o
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
8-K
EX-10.2
dw56l7utwjpkw2u6
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-10.3
95879rf3mg
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
425
dq8tgc18b
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-10.2
81jy9bv uwxsuqokf
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.1
jncajpi4 6fzdn54
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.3
iyvx4d2b
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-2.1
tmk9kenvz2
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.2
w1ng517ej15
7 Nov 18
Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume
4:14pm
10-K
u0gwyj ioj9
30 Mar 15
Annual report
12:00am